Medical Oncology

, 30:661 | Cite as

A comparison of measured and estimated glomerular filtration rate for carboplatin dose calculation in stage I testicular seminoma

  • A. Quinton
  • P. Lewis
  • P. Ali
  • C. Morgan
  • G. Bertelli
Original Paper


Dose calculation of adjuvant carboplatin chemotherapy for stage I testicular seminoma, based on area under the concentration curve (AUC), incorporates the glomerular filtration rate (GFR). This retrospective study compares ‘gold standard’ 51Cr-ethylenediamine tetraacetic acid (51Cr-EDTA) GFR measurements with renal function estimations derived from the Cockcroft–Gault, Jelliffe and Wright formulae. Inclusion criteria: stage I testicular seminoma treated with a single dose of carboplatin AUC7 at one centre in South Wales, UK, between 2005 and 2011, with contemporaneous 51Cr-EDTA GFR measurement and serum creatinine. Renal function estimates obtained using Cockcroft–Gault, Jelliffe and Wright formulae were analysed for bias (mean percentage error, MPE) and precision (mean absolute percentage error, MAPE) compared to the gold standard. Sixty-eight patients were identified, median age 40 (range 17–66), median creatinine 82 (range 55–120). For the Cockcroft–Gault, Jelliffe and Wright formulae, respectively, MPE was +12.4, −32.3 and +8.8; MAPE was 16.0, 32.7 and 12.9; and substitution of the calculated GFR result for 51Cr-EDTA measurement would have resulted in a >10 % discrepancy in carboplatin dose in 41.1, 97.1 and 42.6 % of patients (predominantly overdoses for the Cockcroft–Gault and Wright formulae, underdoses for the Jelliffe formula). Of the formulae analysed, none accurately correlated with 51Cr-EDTA GFR measurements.


Carboplatin Cockcroft–Gault Jelliffe Renal function Seminoma Wright 


Conflict of interest

The authors have declared no conflicts of interest.


  1. 1.
    Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v140–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20(22):4448–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293–300.PubMedCrossRefGoogle Scholar
  4. 4.
    Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748–56.PubMedGoogle Scholar
  5. 5.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Jelliffe RW. Letter: creatinine clearance: bedside estimate. Ann Intern Med. 1973;79(4):604–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer. 2001;84(4):452–9.PubMedCrossRefGoogle Scholar
  8. 8.
    DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med. 1916;17:863–71.CrossRefGoogle Scholar
  9. 9.
    Brochner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest. 1972;30(3):271–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res. 2006;12(21):6502–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Gore M. Carboplatin equals cisplatin: but how do I prescribe it? J Clin Oncol. 2003;21(17):3183–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG. Evaluation of the Cockcroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15(2):291–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Poole SG, Dooley MJ, Rischin D. A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol. 2002;13(6):949–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Holweger K, Lipp HP, Dietz K, Hartmann JT, Bokemeyer C. Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother. 2008;42(12):1749–57.PubMedCrossRefGoogle Scholar
  17. 17.
    Nagao S, Fujiwara K, Imafuku N, Kagawa R, Kozuka Y, Oda T, Maehata K, Ishikawa H, Koike H, Aotani E, Kohno I. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffem, Wright or Chatelut formula. Gynecol Oncol. 2005;99(2):327–33.PubMedCrossRefGoogle Scholar
  18. 18.
    de Lemos ML, Hsieh T, Hamata L, Levin A, Swenerton K, Djurdjev O, Vu T, Hu F, Conklin J, Malfair Taylor SC. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol. 2006;103(3):1063–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Faluyi OO, Masinghe SP, Hayward RL, Clive S. Accuracy of GFR estimation by the Cockroft and Gault, MDRD, and Wright equations in Oncology patients with renal impairment. Med Oncol. 2012;29(2):755–60.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • A. Quinton
    • 1
  • P. Lewis
    • 3
    • 4
  • P. Ali
    • 2
  • C. Morgan
    • 4
  • G. Bertelli
    • 1
  1. 1.Department of OncologySingleton HospitalSwanseaUK
  2. 2.Nuclear MedicineSingleton HospitalSwanseaUK
  3. 3.Centre for Nanohealth, College of MedicineSwansea UniversitySwanseaUK
  4. 4.Institute of Life Science, College of MedicineSwansea UniversitySwanseaUK

Personalised recommendations